Introduction

The Bruton tyrosine kinase (BTK) regulates B cell and macrophage signaling, development, survival, and activation. Inhibiting BTK has been hypothesized to ameliorate lung injury in patients with severe COVID-19, however clinical outcome data is inconclusive.

Objective

To evaluate the clinical outcomes of BTK inhibitors (BTKinibs) in patients with COVID-19.

Evidence review

We searched PubMed, Embase, and Web of Science:Core on December 30, 2020. Clinical studies with at least 5 COVID-19 patients treated with BTKinibs were included. Case reports and reviews were excluded.

Findings

125 articles were identified, 6 of which met inclusion criteria. The most common clinical outcomes measured were oxygen requirements (4/6) and hospitalization rate or duration (3/6). Three studies showed decreased oxygen requirements in patients who started or continued BTKinibs. All three studies that evaluated hospitalization rate or duration found favorable outcomes in those on BTKinibs.

Conclusions and relevance

BTKinib use was associated with decreased oxygen requirements and decreased hospitalization rates and duration.

中文翻译：

---

严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 的 BTK 抑制剂：系统评价

介绍

布鲁顿酪氨酸激酶 (BTK) 调节 B 细胞和巨噬细胞信号、发育、存活和激活。抑制 BTK 已被假设可改善重症 COVID-19 患者的肺损伤，但临床结果数据尚无定论。

客观的

评估 BTK 抑制剂 (BTKinibs) 在 COVID-19 患者中的临床结果。

证据审查

我们在 2020 年 12 月 30 日检索了 PubMed、Embase 和 Web of Science:Core。纳入了至少 5 名接受 BTKinib 治疗的 COVID-19 患者的临床研究。病例报告和评论被排除在外。

发现

确定了 125 篇文章，其中 6 篇符合纳入标准。最常见的临床结果是氧气需求量 (4/6) 和住院率或住院时间 (3/6)。三项研究表明，开始或继续使用 BTKinib 的患者需氧量减少。所有三项评估住院率或持续时间的研究都在 BTKinib 的患者中发现了有利的结果。

结论和相关性

BTKinib 的使用与氧气需求减少、住院率和住院时间减少有关。